{"url_path":"/sec/ltrn/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1763950/0001493152-26-023740-index.html","accession_number":"0001493152-26-023740","cik":"0001763950","ticker":"LTRN","issuer_name":"Lantern Pharma Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1763950/0001493152-26-023740-index.html","primary_entity_key":"0001763950","primary_entity_name":"Lantern Pharma Inc."},"word_count":363,"has_tables":true,"body_markdown":"**Item\n6. Exhibits.**\n\n \n\n**Exhibit**\n\n**No.**\n\n \n**Exhibit\nDescription**\n \n**Method\nof Filing**\n\n3.1\n \n[Amended and Restated Certificate of Incorporation](https://www.sec.gov/Archives/edgar/data/1763950/000121390020015132/ea123112ex3-1v_lantern.htm)\n \nIncorporated\nby reference from the Registrant’s Current Report on Form 8-K filed June 17, 2020\n\n \n \n \n \n \n\n3.2\n \n[By-Laws](https://www.sec.gov/Archives/edgar/data/1763950/000121390020009332/ea120601fs1ex3-1iv_lantern.htm)\n \nIncorporated\nby reference from the Registrant’s Registration Statement on Form S-1 filed April 16, 2020\n\n \n \n \n \n \n\n3.3\n \n[Amendment No. 1 to By-Laws](https://www.sec.gov/Archives/edgar/data/1763950/000149315224021353/ex3-2.htm)\n \nIncorporated\nby reference from the Registrant’s Current Report on Form 8-K filed May 24, 2024\n\n \n \n \n \n \n\n3.4\n \n[Amendment No. 2 to By-Laws](https://www.sec.gov/Archives/edgar/data/1763950/000164117225021407/ex3-2.htm)\n \nIncorporated\nby reference from Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed July 29, 2025\n\n \n \n \n \n \n\n31.1\n \n[Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ex31-1.htm)\n \nFiled\nelectronically herewith\n\n \n \n \n \n \n\n31.2\n \n[Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ex31-2.htm)\n \nFiled\nelectronically herewith\n\n \n \n \n \n \n\n32.1\n \n[Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ex32-1.htm)\n \nFurnished\nelectronically herewith\n\n \n \n \n \n \n\n32.2\n \n[Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ex32-2.htm)\n \nFurnished\nelectronically herewith\n\n \n \n \n \n \n\n101.INS\n \nInline\nXBRL Instance Document.\n \nFiled\nelectronically herewith\n\n \n \n \n \n \n\n101.SCH\n \nInline\nXBRL Taxonomy Extension Schema Document.\n \nFiled\nelectronically herewith\n\n \n \n \n \n \n\n101.CAL\n \nInline\nXBRL Taxonomy Extension Calculation Linkbase Document.\n \nFiled\nelectronically herewith\n\n \n \n \n \n \n\n101.DEF\n \nInline\nXBRL Taxonomy Extension Definition Linkbase Document.\n \nFiled\nelectronically herewith\n\n \n \n \n \n \n\n101.LAB\n \nInline\nXBRL Taxonomy Extension Label Linkbase Document.\n \nFiled\nelectronically herewith\n\n \n \n \n \n \n\n101.PRE\n \nInline\nXBRL Taxonomy Extension Presentation Linkbase Document.\n \nFiled\nelectronically herewith\n\n \n \n \n \n \n\n104\n \nCover\nPage Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).\n \nFiled\nelectronically herewith\n\n \n\n24\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned thereunto duly authorized.\n\n \n\n \nLantern\nPharma Inc.,\n\n \n \n\n \nA\nDelaware Corporation\n\n \n \n \n\nDated:\nMay 15, 2026\nBy:\n*/s/\nPanna Sharma*\n\n \n \nPanna\nSharma, Chief Executive Officer\n\n \n \n \n\nDated:\nMay 15, 2026\nBy:\n*/s/\nDavid R. Margrave*\n\n \n \nDavid\nR. Margrave, Chief Financial Officer\n\n \n\n25"}